Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > RP2D

<< Previous

Bullboard Posts

Next >>

Comment by LouisWon Jan 21, 2022 2:02am

193 Views

Post# 34341029

RE:RE:RE:RP2D

To me, the progress is accetable despite it is slower than what i was expecting. If they encounter DLT in multiple patients, they will be forced to step down to 1.5x dosage. At least, they are evaluating 2X dosage and not experiencing any DLT yet. I am totally fine if MTD is 2x dosage.

Yesterday, XBI was down 1.6%, however, THTX was up 3% with . Coincidentally, TH has clarified the clinical progress which is evaluating 2x dosage after the market. So i am wondering if the progress is considered positive by the market....I maybe wrong but we will find out today.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects